JPRN-UMIN000013659已完成未知
Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH) - Efficacy of Denosumab for steroid-induced osteoporosis in patients with AIH
Juntendo University School of Medicine0 个研究点目标入组 80 人开始时间: 2014年4月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Cancer patients with bone metastasis or expected bone metastasis 2) Hypocalcemia 3) Women who wish to be pregnant or are pregnant, or in lactation 4)Hypersensitivity to the denosumab 5)Cancer patients on cancer treatment or anti-hormonal therapy 6)Dental therapy during this trial 7)Long term use of bisphosphonate and have the possibility of atypical fracture 8)severe skin infection 9)severe impaired renal function (Serum creatinine levels: 2.0mg/dl and higher)
研究者
相似试验
已完成
不适用
Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosisOsteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonateJPRN-UMIN000012193Juntendo University School of Medicine60
已完成
不适用
Efficacy of anti-RANKL human antibody (Denosumab) on prevention of osteoporosis with primary biliary cirrhosisOsteoporosis in biopsy-proven PBC who was not pretreated with denosumab and/or bisphosphonate in recent 6 monthsJPRN-UMIN000012489Juntendo University School of Medicine20
已完成
不适用
Efficacy of anti-RANKL antibody on bone and mineral disorders in post-kidney transplant patients.Bone and mineral disorders after kidney transplantationJPRN-UMIN000013268Fujita Health University31
进行中（未招募）
1 期
Effects of a treatment with Denosumab, applied together with either Nivolumab oder Pembrolizumab, in patients with skin cancer and bone metastasesEUCTR2016-001925-15-DEAlcedis GmbH20
已完成
4 期
Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant melanoma with bone involvementC43.9C79.5Malignant melanoma of skin, unspecifiedSecondary malignant neoplasm of bone and bone marrowDRKS00016064Alcedis GmbH17